Dtsch Med Wochenschr 2018; 113(13): 937-944
DOI: 10.1055/a-0612-3564
Dossier
© Georg Thieme Verlag KG Stuttgart · New York

Chronisch entzündliche Darmerkrankungen: Leitsymptome und Diagnostik

Inflammatory bowel disease: cardinal signs and their diagnostics
Donata Lissner
,
Elena Sonnenberg
,
Britta Siegmund
Further Information

Publication History

Publication Date:
04 July 2018 (online)

Abstract

Inflammatory bowel diseases, including Crohn’s disease and ulcerative colitis, often occur early in life. Therefore, they affect our patient’s individual path of life, their ability to work and the quality of life tremendously, which calls for close and comprehensive medical care. This article features 5 cardinal signs and their diagnostics.

Die chronisch entzündlichen Darmerkrankungen Morbus Crohn und Colitis ulcerosa begleiten die bei Erstdiagnose meist jungen Patienten ein Leben lang. Je nach Ausprägung beeinflussen sie die Lebensqualität, Erwerbsfähigkeit und den persönlichen Lebensweg unserer Patienten immens, was eine enge und umfassende Betreuung erfordert. In diesem Beitrag werden praxisrelevant 5 Leitsymptome und die entsprechende Diagnostik zusammengefasst.

 
  • Literatur

  • 1 Magro F, Gionchetti P, Eliakim R. et al. Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 1. J Crohns Colitis 2017; 11 (06) 649-670
  • 2 Ben-Horin S, Margalit M, Bossuyt P. et al. Prevalence and clinical impact of endoscopic pseudomembranes in patients with inflammatory bowel disease and Clostridium difficile infection. J Crohns Colitis 2010; 4 (02) 194-198
  • 3 Corte C, Fernandopulle N, Catuneanu AM. et al. Association between the ulcerative colitis endoscopic index of severity (UCEIS) and outcomes in acute severe ulcerative colitis. J Crohns Colitis 2015; 9 (05) 376-381
  • 4 Peyrin-Biroulet L, Reinisch W, Colombel JF. et al. Clinical disease activity, C-reactive protein normalisation and mucosal healing in Crohn’s disease in the SONIC trial. Gut 2014; 63 (01) 88-95
  • 5 Silverberg MS, Satsangi J, Ahmad T. et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: re-port of a working party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol 2005; 19: 5A-36A
  • 6 Satsangi J, Silverberg MS, Vermeire S. et al. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut 2006; 55: 749-753
  • 7 Gomollón F, Dignass A, Annese V. et al. 3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn’s Disease 2016: Part 1: Diagnosis and Medical Management. J Crohns Colitis 2017; 11 (01) 3-25
  • 8 Kratzer W, von Tirpitz C, Mason R. et al. Contrast-enhanced power Doppler sonography of the intestinal wall in the differentiation of hypervascularized and hypovascularized intestinal obstructions in patients with Crohn’s disease. J Ultrasound Med 2002; 21: 149-157
  • 9 Kucharzik T, Wittig BM, Helwig U. et al. Use of Intestinal Ultrasound to Monitor Crohn’s Disease Activity. Clin Gastroenterol Hepatol 2017; 15 (04) 535-542
  • 10 Fumery M, Pineton de Chambrun G, Stefanescu C. et al. Detection of Dysplasia or Cancer in 3.5% of Patients With Inflammatory Bowel Disease and Colonic Strictures. Clin Gastroenterol Hepatol 2015; 13 (10) 1770-1775
  • 11 Rimola J, Planell N, Rodríguez S. et al. Characterization of inflammation and fibrosis in Crohn’s disease lesions by magnetic resonance imaging. Am J Gastroenterol 2015; 110 (03) 432-440
  • 12 Gasche C, Moser G, Turetschek K. et al. Transabdominal bowel sonography for the detection of intestinal complications in Crohn’s disease. Gut 1999; 44: 112-117
  • 13 Martinez MJ, Ripolles T, Paredes JM. et al. Assessment of the extension and the inflammatory activity in Crohn’s disease. Abdom Imaging 2009; 34: 141-148
  • 14 Potthast S, Rieber A, Von Tirpitz C. et al. Ultrasound and magnetic resonance imaging in Crohn’s disease: a comparison. Eur Radiol 2002; 12: 1416-1422
  • 15 Vavricka SR, Brun L, Ballabeni P. et al. Frequency and risk factors for extraintestinal manifestations in the Swiss inflammatory bowel disease cohort. Am J Gastroenterol 2011; 106: 110-119
  • 16 Dignass A, Preiß JC, Aust DE. Aktualisierte Leitlinie zur Diagnostik und Therapie der Colitis ulcerosa 2011. Z Gastroenterol 2011; 49: 1276-1341
  • 17 Harbord M, Annese V, Vavricka S. et al. The First European Evidence-based Consensus on Extra-intestinal Manifestations in Inflammatory Bowel Disease. J Crohns Colitis 2016; 10 (03) 239-254
  • 18 Sarzi-Puttini P, Ardizzone S, Manzionna G. et al. Infliximab-induced lupus in Crohn’s disease: a case report. Dig Liver Dis 2003; 35: 814-817
  • 19 Brooklyn T, Dunnill G, Probert C. Diagnosis and treatment of pyoderma gangrenosum. BMJ 2006; 333: 181-184
  • 20 Cohen BL, Zoega H, Shah SA. et al. Fatigue is highly associated with poor health-related quality of life, disability and depression in newly-diagnosed patients with inflammatory bowel disease, independent of disease activity. Aliment Pharmacol Ther 2014; 39: 811-822
  • 21 Danese S, Hoffman C, Vel S. et al. Anaemia from a patient perspective in inflammatory bowel disease. Eur J Gastroenterol Hepatol 2014; 26 (12) 1385-1391
  • 22 Vagianos K, Bector S, McConnell J. et al. Nutrition assessment of patients with inflammatory bowel disease. JPEN J Parenter Enteral Nutr 2007; 31: 311-319